Unknown

Dataset Information

0

Cortico-Amygdala-Striatal Activation by Modafinil/Flecainide Combination.


ABSTRACT: Background:Modafinil, a nonamphetaminic wake-promoting compound, is prescribed as first line therapy in narcolepsy, an invalidating disorder characterized by excessive daytime sleepiness and cataplexy. Although its mode of action remains incompletely known, recent studies indicated that modafinil modulates astroglial connexin-based gap junctional communication as administration of a low dose of flecainide, an astroglial connexin inhibitor, enhanced the wake-promoting and procognitive activity of modafinil in rodents and healthy volunteers. The aim of this study is to investigate changes in glucose cerebral metabolism in rodents, induced by the combination of modafinil+flecainide low dose (called THN102). Methods:The impact of THN102 on brain glucose metabolism was noninvasively investigated using 18F-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography imaging in Sprague-Dawley male rats. Animals were injected with vehicle, flecainide, modafinil, or THN102 and further injected with 18F-2-fluoro-2-deoxy-D-glucose followed by 60-minute Positron Emission Tomography acquisition. 18F-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography images were coregistered to a rat brain template and normalized from the total brain Positron Emission Tomography signal. Voxel-to-voxel analysis was performed using SPM8 software. Comparison of brain glucose metabolism between groups was then performed. Results:THN102 significantly increased regional brain glucose metabolism as it resulted in large clusters of 18F-2-fluoro-2-deoxy-D-glucose uptake localized in the cortex, striatum, and amygdala compared with control or drugs administered alone. These regions, highly involved in the regulation of sleep-wake cycle, emotions, and cognitive functions were hence quantitatively modulated by THN102. Conclusion:Data presented here provide the first evidence of a regional brain activation induced by THN102, currently being tested in a phase II clinical trial in narcoleptic patients.

SUBMITTER: Vodovar D 

PROVIDER: S-EPMC6031015 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cortico-Amygdala-Striatal Activation by Modafinil/Flecainide Combination.

Vodovar Dominique D   Duchêne Adeline A   Wimberley Catriona C   Leroy Claire C   Pottier Géraldine G   Dauvilliers Yves Y   Giaume Christian C   Lin Jian-Sheng JS   Mouthon Franck F   Tournier Nicolas N   Charvériat Mathieu M  

The international journal of neuropsychopharmacology 20180701 7


<h4>Background</h4>Modafinil, a nonamphetaminic wake-promoting compound, is prescribed as first line therapy in narcolepsy, an invalidating disorder characterized by excessive daytime sleepiness and cataplexy. Although its mode of action remains incompletely known, recent studies indicated that modafinil modulates astroglial connexin-based gap junctional communication as administration of a low dose of flecainide, an astroglial connexin inhibitor, enhanced the wake-promoting and procognitive act  ...[more]

Similar Datasets

| S-EPMC4391231 | biostudies-literature
| S-EPMC5564682 | biostudies-literature
| S-EPMC5249227 | biostudies-other
| S-EPMC7162658 | biostudies-literature
| S-EPMC6478892 | biostudies-literature
| S-EPMC4955838 | biostudies-literature
| S-EPMC6475612 | biostudies-literature
| S-EPMC3954809 | biostudies-literature
| S-EPMC6541437 | biostudies-literature
| S-EPMC5825262 | biostudies-literature